# A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

> **NCT07728383** · PHASE4 · RECRUITING · sponsor: **Gila Therapeutics, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Obesity & Overweight

## Interventions

- **DRUG:** Semaglutide 6 mg liquid emulsion formulation
- **DRUG:** Wegovy® (semaglutide) Tablet
- **DRUG:** Placebo liquid emulsion formulation

## Key facts

- **NCT ID:** NCT07728383
- **Lead sponsor:** Gila Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-17
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07728383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07728383, "A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07728383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*